A malaria vaccine candidate based on a hepatitis B virus core platform

Area of Science:

• Immunology
• Vaccinology
• Parasitology

Background:

• Recent success of circumsporozoite protein (CSP) based malaria vaccines has renewed interest in pre-erythrocytic vaccine development.
• CSP contains critical T and B cell epitopes for inducing protective immunity against Plasmodium falciparum.
• Developing efficient delivery systems for these epitopes is crucial for effective vaccine design.

Purpose of the Study:

• To design an efficient delivery system for known neutralizing epitopes of Plasmodium falciparum circumsporozoite protein (CSP).
• To create a novel pre-erythrocytic vaccine candidate by combining CSP epitopes with a particulate carrier platform.

Main Methods:

• Conjugation of well-characterized CSP-specific neutralizing B cell epitopes and a universal T cell epitope to a hepatitis B core antigen (HBcAg) particulate carrier platform.
• Production of the hybrid HBcAg-CSP particles using bacterial expression systems.
• Immunization of mice with the V12.PF3.1 vaccine candidate.

Main Results:

• The V12.PF3.1 vaccine candidate is a potent immunogen in mice, inducing high titers (>10^6) of sporozoite-binding antibodies after two doses.
• Generated antibodies are long-lasting, encompass all IgG isotypes, and are not subject to genetic restriction.
• Immunization primes CSP-specific CD4+ T cells in most murine strains.
• The hybrid HBcAg-CS particles are producible inexpensively in bacterial systems.

Conclusions:

• V12.PF3.1 demonstrates potential as an efficient and economical Plasmodium falciparum vaccine candidate.
• The vaccine can be used independently or in conjunction with other malaria vaccine formulations.
• Its characteristics suggest broad applicability and cost-effectiveness for malaria control efforts.